Enovis (NYSE:ENOV) Stock Rating Upgraded by Wall Street Zen

Enovis (NYSE:ENOV) was upgraded by equities researchers at Wall Street Zen from a “hold” rating to a “buy” rating in a report issued on Saturday.

Several other research analysts have also recently weighed in on ENOV. Zacks Research raised shares of Enovis from a “hold” rating to a “strong-buy” rating in a research report on Wednesday, March 4th. BTIG Research raised their price objective on shares of Enovis from $41.00 to $43.00 and gave the stock a “buy” rating in a research report on Thursday, February 26th. Needham & Company LLC lifted their target price on shares of Enovis from $49.00 to $52.00 and gave the stock a “buy” rating in a research note on Thursday, February 26th. Canaccord Genuity Group decreased their target price on shares of Enovis from $58.00 to $50.00 and set a “buy” rating on the stock in a report on Wednesday, December 17th. Finally, Evercore reissued an “outperform” rating on shares of Enovis in a research note on Monday, January 12th. One research analyst has rated the stock with a Strong Buy rating, seven have assigned a Buy rating and one has given a Sell rating to the company. According to MarketBeat, the stock currently has an average rating of “Moderate Buy” and a consensus price target of $47.43.

Enovis Price Performance

NYSE:ENOV opened at $22.99 on Friday. Enovis has a one year low of $21.00 and a one year high of $40.69. The company has a debt-to-equity ratio of 0.85, a quick ratio of 1.04 and a current ratio of 2.02. The stock has a market cap of $1.32 billion, a PE ratio of -1.11 and a beta of 1.46. The stock has a 50 day moving average price of $23.81 and a 200 day moving average price of $27.78.

Enovis (NYSE:ENOV) last released its quarterly earnings data on Thursday, February 26th. The company reported $0.95 earnings per share for the quarter, topping analysts’ consensus estimates of $0.81 by $0.14. The company had revenue of $575.76 million for the quarter, compared to analyst estimates of $584.30 million. Enovis had a positive return on equity of 8.74% and a negative net margin of 52.69%.The firm’s revenue for the quarter was up 2.6% compared to the same quarter last year. During the same quarter in the previous year, the company posted $0.98 earnings per share. Enovis has set its FY 2026 guidance at 3.520-3.730 EPS. Equities research analysts expect that Enovis will post 2.79 EPS for the current fiscal year.

Insider Activity

In other Enovis news, insider Oliver Engert acquired 1,000 shares of the business’s stock in a transaction that occurred on Friday, February 27th. The stock was purchased at an average cost of $25.50 per share, with a total value of $25,500.00. Following the transaction, the insider owned 43,640 shares of the company’s stock, valued at $1,112,820. This trade represents a 2.35% increase in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available at this hyperlink. Over the last three months, insiders bought 4,000 shares of company stock worth $98,243. 2.70% of the stock is currently owned by company insiders.

Institutional Inflows and Outflows

Hedge funds have recently bought and sold shares of the stock. River Road Asset Management LLC raised its stake in shares of Enovis by 3.2% in the 4th quarter. River Road Asset Management LLC now owns 1,487,277 shares of the company’s stock valued at $39,621,000 after acquiring an additional 46,289 shares during the period. Corient Private Wealth LLC boosted its position in shares of Enovis by 540.7% during the 4th quarter. Corient Private Wealth LLC now owns 55,180 shares of the company’s stock worth $1,470,000 after purchasing an additional 46,568 shares during the period. Front Street Capital Management Inc. boosted its position in shares of Enovis by 75.8% during the 4th quarter. Front Street Capital Management Inc. now owns 361,932 shares of the company’s stock worth $9,642,000 after purchasing an additional 156,069 shares during the period. XTX Topco Ltd acquired a new stake in Enovis in the 4th quarter valued at approximately $561,000. Finally, Susquehanna Portfolio Strategies LLC raised its position in Enovis by 249.9% in the fourth quarter. Susquehanna Portfolio Strategies LLC now owns 140,997 shares of the company’s stock valued at $3,756,000 after purchasing an additional 100,704 shares during the period. Hedge funds and other institutional investors own 98.45% of the company’s stock.

About Enovis

Enovis is a global medical technology company focused on advancing the field of musculoskeletal health. Formed through the separation of the MedTech business from Colfax Corporation in 2021, Enovis brings together a portfolio of specialized products and services designed to address conditions affecting the foot and ankle, hand and wrist, sports medicine, joint repair, biologics and rehabilitation.

The company’s flagship offerings include minimally invasive implants and instrumentation for foot and ankle surgery under the Treace Medical Concepts brand, focal joint resurfacing implants through Arthrosurface, and synthetic bone graft substitutes marketed as NovaBone.